Investment Analysts’ Weekly Ratings Updates for Taysha Gene Therapies (TSHA)

A number of firms have modified their ratings and price targets on shares of Taysha Gene Therapies (NASDAQ: TSHA) recently:

• 6/30/2026 – Taysha Gene Therapies had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $12.00 price target on the stock.
• 6/30/2026 – Taysha Gene Therapies had its price target raised by Robert W. Baird from $12.00 to $15.00. They now have an “outperform” rating on the stock.
• 6/24/2026 – Taysha Gene Therapies had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/23/2026 – Taysha Gene Therapies was given a new $14.00 price target by Pivotal Research.
• 6/23/2026 – Taysha Gene Therapies had its price target raised by BMO Capital Markets from $10.00 to $14.00. They now have an “outperform” rating on the stock.
• 6/23/2026 – Taysha Gene Therapies had its “outperform” rating reaffirmed by Citigroup Inc..
• 6/23/2026 – Taysha Gene Therapies had its price target raised by Citizens Jmp from $8.00 to $11.00. They now have a “market outperform” rating on the stock.
• 6/22/2026 – Taysha Gene Therapies had its price target raised by Bank of America Corporation from $9.00 to $10.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Taysha Gene Therapies had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $12.00 price target on the stock.
• 5/9/2026 – Taysha Gene Therapies was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Buying and Selling at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the transaction, the insider directly owned 1,136,410 shares of the company’s stock, valued at $5,068,388.60. The trade was a 14.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company’s stock.

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.